Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (271-280 of 755) with videos related to

Pageof 76
Sort By:
Rheumatology (Oxford, England)|February 18, 2011
Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life studyTracy Frech, Ron D Hays, Paul Maranian, et al.
AJR. American Journal of Roentgenology|June 1, 1981
Skeletal findings in progressive systemic sclerosis (scleroderma)L W Bassett, K L Blocka, D E Furst, et al.
The Journal of Rheumatology|July 1, 1990
Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucilP J Clements, J B Peter, M S Agopian, et al.
Arthritis and Rheumatism|April 12, 2011
Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitorsRobert A Terkeltaub, Daniel E Furst, Jennifer L Digiacinto, et al.
Seminars in Arthritis and Rheumatism|August 15, 2015
A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damageChristophe Meune, Dinesh Khanna, Jamil Aboulhosn, et al.
The Journal of Rheumatology|August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsRonald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
The Journal of Rheumatology|October 11, 2002
Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritisNihal H Fathi, Frank Mitros, John Hoffman, et al.
Current Rheumatology Reviews|August 3, 2010
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study DesignDinesh Khanna, James R Seibold, Athol Wells, et al.
Lupus|October 9, 2012
Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care populationD E Furst, A E Clarke, A W Fernandes, et al.
Arthritis and Rheumatism|August 1, 1990
Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosisP J Clements, P A Lachenbruch, S C Ng, et al.
Pageof 76

Showing results (271-280 of 755) with videos related to

Sort By:
Pageof 76
Rheumatology (Oxford, England)|February 18, 2011
Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life studyTracy Frech, Ron D Hays, Paul Maranian, et al.
AJR. American Journal of Roentgenology|June 1, 1981
Skeletal findings in progressive systemic sclerosis (scleroderma)L W Bassett, K L Blocka, D E Furst, et al.
The Journal of Rheumatology|July 1, 1990
Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucilP J Clements, J B Peter, M S Agopian, et al.
Arthritis and Rheumatism|April 12, 2011
Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitorsRobert A Terkeltaub, Daniel E Furst, Jennifer L Digiacinto, et al.
Seminars in Arthritis and Rheumatism|August 15, 2015
A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damageChristophe Meune, Dinesh Khanna, Jamil Aboulhosn, et al.
The Journal of Rheumatology|August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsRonald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
The Journal of Rheumatology|October 11, 2002
Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritisNihal H Fathi, Frank Mitros, John Hoffman, et al.
Current Rheumatology Reviews|August 3, 2010
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study DesignDinesh Khanna, James R Seibold, Athol Wells, et al.
Lupus|October 9, 2012
Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care populationD E Furst, A E Clarke, A W Fernandes, et al.
Arthritis and Rheumatism|August 1, 1990
Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosisP J Clements, P A Lachenbruch, S C Ng, et al.
Pageof 76